SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Lynch TJ, Kalish L, Strauss G, et al. Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol. 1994; 12: 347352.
  • 2
    Perez-Soler R, Fossella FV, Glisson BS, et al. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol. 1996; 14: 503513.
  • 3
    White SC, Cheeseman S, Anderson H, et al. A phase II study of oral topotecan in advanced non-small cell lung cancer: useful symptom palliation and 10 month median survival [abstract]. Proc Am Soc Clin Oncol. 1999; 2033: 527A.
  • 4
    Shahab N, Perry MC. DNA Topoisomerase Inhibitors. In: PerryM, editor. The chemotherapy sourcebook. Baltimore: Williams and Wilkins, 1997: 425433.
  • 5
    Stewart CF, Ratain MJ. Topoisomerase interactive agents. In: DevitaVT, HellmanS, RosenbergSA, editors. Cancer: principles and practice of oncology, 6th ed. Philadelphia: Lippincott, Williams, and Wilkins, 2001: 416425.
  • 6
    Budman DR, Lichtman SM. Investigational drugs. In: PerryM, editor. The chemotherapy sourcebook. Baltimore: Williams and Wilkins, 1997: 502503.
  • 7
    Chu E, Mota AC, Fogarasi MC. Antimetabolites. In: DevitaVT, HellmanS, RosenbergSA, editors. Cancer: principles and practice of oncology, 6th ed. Philadelphia: Lippincott, Williams, and Wilkins, 2001: 402404.
  • 8
    Hansen HH, Sorensen JB. Efficacy of single-agent gemcitabine in advanced non-small-cell lung cancer: a review. Semin Oncol. 1997; 24 (Suppl 7): 3841.
  • 9
    Belani CP. Single agents in the second-line treatment of non-small cell lung cancer. Semin Oncol. 1998; 25(2 Suppl 8 ): 1014.
  • 10
    Huisman C, Smit EF, Giaccone G, Postmus PE. Second-line chemotherapy in relapsing or refractory non-small cell lung cancer: a review. J Clin Oncol. 2000; 18: 37223730.
  • 11
    Dabrow MB, Gilman PB, Meyer TJ. Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol. 1999; 1930: 500.
  • 12
    Rinaldi D, Lormand N, Brierre J, et al. A phase I-II trial of topotecan and gemcitabine in patients with previously treated, advanced non-small cell lung cancer (LOA-3). Cancer Invest. 2001; 19: 467474.
  • 13
    World Health Organization. The WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979.
  • 14
    Sculier JP, Lafitte JJ, Berghmans T, et al. for the European Lung Cancer Working Party. A phase II trial testing gemcitabine as second-line chemotherapy for non-small cell lung cancer. Lung Cancer. 2000; 29: 6773.
  • 15
    Crino L, Mosconi AM, Scagliotti G, et al. Gemcitabine as second-line treatment for advanced non-small cell lung cancer: a phase II trial. J Clin Oncol. 1999; 17: 20812085.
  • 16
    Fosella FV, Lee JS, Shin DM, et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol. 1995; 13: 645651.
  • 17
    Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol. 2000; 18: 23542362.
  • 18
    Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000; 18: 20952103.
  • 19
    Alexopoulos K, Kouroussis C, Androulakis N, et al. Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial. Cancer Chemother Pharmacol. 1999; 43: 257262.
  • 20
    Gandara DR, Voakes E, Green M, et al. Activity of docetaxel in platinum-treated non-small cell lung cancer: results of a phase II multicenter Trial. J Clin Oncol. 2000; 18: 131135.